Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of TAK-994 in Healthy Subjects
NCT03933488Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of firazorexton in narcolepsy type 1 (NT1) (5 arms), sponsored by Takeda. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events, Number of Participants With at Least one Markedly Abnormal Laboratory Value and 2 more. Started May 2019; status: completed.
02
Drugs
firazorexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT03933488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933488.